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ABSTRACT 
 
 
Objective: To better understand the characteristics of patients with persistently 
high pain scores (mean ≥ 7) as compared to those with persistently low to 
moderate pain scores (mean ≤ 6). 
Design: This study was a retrospective chart review that compares high pain 
patients with sickle cell disease (SCD) and low-moderate pain patients with SCD 
that were admitted between 2010- 2011. Each chart was reviewed for information 
relating to demographics, location of pain, clinical course, school progress and 
family structure. Any numerical measures were compared using t- tests to assess 
whether differences in mean values were of significance.  
Results: High pain admissions showed no significant differences in BMI or 
hemoglobin levels at admission from low-moderate pain admissions. (p= 0.163 
 v 
and p=0.424, respectively).  Mean length of stay (p=0.048) and total length of 
stay within the two-year period (p=0.002) was significantly greater in high pain 
admissions. Patients in both groups had similar clinical courses, co-morbidities, 
long-term medications, hydroxyurea compliance, family structure and school 
progress.   
Discussion: Although some factors of high pain patients differed from low pain 
patients, these differences do not warrant any changes in the form of care for 
one particular group. 
Conclusion: Development of a method of intervention that can be administered 
early in order to decrease the number of pain crises would prove to be a 
beneficial use of resources. The use of a pain tool specific to SCD could help to 
standardize pain scores within this population.  
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INTRODUCTION 
 
Sickle cell disease (SCD) is a category of disorders that affect 
hemoglobin, which is the protein within red blood cells (RBCs) responsible for 
binding and transporting oxygen to tissues within the body. It is a common 
genetic disorder, which affects 70,000-100,000 people within the United States, 
primarily blacks or African Americans (National Heart Lung and Blood Institute, 
2012). The Centers for Disease Control and Prevention (CDC) estimate that SCD 
occurs in one out of every 500 black or African-American births, and 
approximately one in every 36,000 Hispanic-American births (CDC, 2011).  
People with the disorder have atypical hemoglobin, titled hemoglobin S 
(HbS), which makes sickle-shaped red blood cells instead of healthy, disc-
shaped ones. Unlike normal red blood cells, which move smoothly through 
capillaries and other blood vessels, these sickle-shaped red blood cells are stiffer 
and stick together, blocking blood vessels of the limbs and organs. The lack of 
blood flow that results can lead to organ damage as well as severe ischemic 
pain. Chronic, unpredictable pain is the most frequent complication of SCD, 
interfering with quality of life and requiring hospitalizations (Barakat et al, 2010). 
Chronic pain is defined as pain that persists for three months or more (Ballas et 
al, 2012). Common causes of chronic pain in patients with sickle cell disease are 
bone infarction, avascular necrosis of joints, back pain due to disk protrusion into 
vertebral bodies, leg ulcers, and chronic osteomyelitis (Ballas et al 2012). 
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Complications such as stroke and infections contribute to high morbidity and 
mortality rates in this population.  
Although many patients with SCD are now surviving well into adulthood, 
this was not always the case. From 1910 to 1950, most patients with SCD had a 
lifespan of <20 years. By 1980, 50% of children survived to the age of 20. As of 
2009, 85% of children with SCD survive to age 20 (Ballas et al, 2012). Newborn 
screening and early administration of penicillin prophylaxis may have contributed 
to this jump in life expectancy. Platt et al. (1994) reported that the peak incidence 
of death within children with SCD occurs between the ages of one and three and 
can be attributed primarily to pneumococcal sepsis. Deaths that occur in older 
aged patients are caused by a multitude of causes including acute chest 
syndrome and organ-system failure (Platt et al., 1994).  
Hemoglobin  
Hemoglobin has a quaternary structure, which consists of four globular 
protein subunits held together by a combination of weak forces. Each subunit of 
hemoglobin is made of a protein chain closely connected to a non-protein heme 
group. Hemoglobin’s unique structure facilitates cooperative binding, which 
allows for efficient oxygen and carbon dioxide transport. In normal adults, the 
most common form of hemoglobin is hemoglobin A (HbA), which has two alpha 
subunits consisting of 141 amino acid residues and two beta subunits made of 
146 amino acid residues. The typical expression of the Hemoglobin beta chain 
gene (HBB) results in the creation of the beta globin. One of many possible 
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mutations in the HBB gene leads to the formation of HbS. The hemoglobin of 
patients with SCD contains HbS subunits instead of the normal beta globin 
subunits, though the alpha subunits remain unchanged. HbS differs from beta 
globin by one amino acid: valine replaces glutamic acid at position six in the 
amino acid chain. The deoxygenated form of HbS has a higher tendency to 
sickle, thus a decrease in oxygen in the blood can have dangerous effects. For 
this reason, spending time at high altitudes and airplane travel pose risks to 
people with SCD.  
Sickle cell disease is an autosomal recessive disease, meaning that both 
copies of the gene in each cell have to contain mutations in order for a person to 
have the disease and exhibit symptoms. These patients have HbSS, the type of 
sickle cell disease that is commonly referred to as sickle cell anemia. If only one 
beta chain is replaced by HbS, the person has the sickle cell trait and is 
considered a carrier. The CDC estimates that approximately one in 12 African 
Americans possess the sickle cell trait (CDC, 2012). Carriers are often unaware 
of their status since they do not exhibit symptoms. The sickle cell trait is 
beneficial to some since it partially protects against malaria. For this reason, 
people with the sickle cell trait are more likely to survive in populations where 
malaria is endemic. When these people go on to have offspring, they pass on the 
sickle cell trait.  
The severity of sickle cell disease varies according to the genotype and 
phenotype. In addition to HbSS, other common forms of sickle cell include HbSC 
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and HbS beta thalassemia (CDC, 2011). People that have HbSC have one copy 
of the sickle cell gene, which accounts for the “S” and have one copy of abnormal 
hemoglobin called “hemoglobin C.” Hemoglobin C results from a substitution of a 
lysine in place of a glutamic acid amino acid in the sixth position of the HBB 
gene. This mutated hemoglobin also reduces the normal flexibility of RBCs, 
contributing to the complications of SCD. People with HbS beta thalassemia 
inherit one copy of the sickle gene “S” from one parent and inherit a gene for 
beta thalassemia from the other parent. Beta thalassemia is a type of 
thalassemia that results from mutations in the HBB gene. It is inherited in an 
autosomal recessive fashion. Beta thalassemia is characterized as either 
thalassemia major or thalassemia intermedia, according to the severity of the 
symptoms. Thalassemia major is more severe and patients often present with 
symptoms earlier in life than people with thalassemia intermedia (National 
Institutes of Health, 2013). There are also different forms of the mutation that 
cause beta thalassemia, but they are not a direct indicator of the severity of 
symptoms. Beta-zero thalassemia occurs when there is no beta globin produced 
at all. People with beta-plus thalassemia are able to make beta globin, but only in 
limited amounts.  All forms of sickle cell result in impaired hemoglobin and RBCs 
with less flexibility, increasing the chances for vaso-occlusive crises and resultant 
pain.  
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Sickle Cell Pathogenesis 
RBCs are formed within the bone marrow and circulate through the blood 
vessels of the body for approximately 120 days. Once they have reached their 
peak, the spleen is responsible for removing them. All RBCs enter the splenic 
cords, which act as a filter, only allowing those of acceptable size, shape and 
elasticity to pass. Unacceptable RBCs are removed from the circulation and 
phagocytized by macrophages. Iron within the RBC is extracted and recycled to 
the bone marrow. Because the RBCs of patients with sickle cell disease are 
stiffer and crescent shaped, they are often removed from circulation prematurely, 
shortening their lifespan to 10 to 20 days. The destruction or rupture of RBCs is 
termed hemolysis. The shortage of circulating RBCs decreases the availability of 
oxygen to the tissues of the body. The condition is known as anemia and may 
lead to fatigue, shortness of breath, chest pain, dizziness, headache and 
cognitive problems (Mayo Foundation for Medical Education and Research, 
2011). Due to the spleen’s role as a filter of RBCs, it is commonly one of the first 
organs negatively affected by sickle cell disease. Often, the spleen is enlarged 
during the first decade of life but it atrophies with age and its blood supply 
becomes repeatedly occluded, eventually leading to autosplenectomy in many 
patients with SCD (Al-Salem, 2011). Without a functioning spleen, patients with 
SCD are at a greater risk for contracting infections. Additional factors such as 
abnormalities of opsonization, antibody protection, the alternate complement 
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pathway, leukocyte functions and cell- mediated immunity also increase the 
susceptibility of patients with SCD to infections (Ahmed, 2011).  
When a person with SCD experiences a vaso-occlusive crisis (VOC), the 
severe pain that results often requires inpatient management as well as the 
administration of opioids. Many studies support the idea that a VOC can be 
broken into phases (Beyer et al., 1999, Jacob et al., 2005) Jacob et al (2005) 
named the four phases: prodromal, initial, established, and resolving. The 
prodromal phase results in aches, numbness and paresthesias, lasting for three 
days and occurring pre-crisis. The second phase is the initial, evolving and 
infarctive phase where the pain gradually increases from aches to maximum 
intensity pain. Phase three is the established phase, which lasts approximately 
four to five days and consists of steady and severe pain. The fourth phase is 
resolving post-crisis which usually lasts one to two days and involves a gradual 
decrease in the intensity of pain. Ballas et al (2012) found that patients with acute 
painful crises typically receive treatment approximately two to three days after 
the start of the early prodromal signs. They stressed the importance of patients 
with SCD receiving care earlier in the process of the VOC, in order to prevent the 
tissue damage that occurs during the prodromal phase.  
Acute chest syndrome (ACS) is the result of a VOC that blocks the 
pulmonary vasculature and causes a new pulmonary infiltrate on x-ray. The 
resulting symptoms include: “fever, cough, tachypnea, chest pain and shortness 
of breath” (Danielson, 2002). ACS is the second most common reason for 
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hospitalization in patients with sickle cell disease (Vichinsky et al., 1997). ACS 
progresses rapidly and must be treated immediately with blood gas monitoring, 
oxygen therapy, pain management to avoid splinting, the use of antibiotics and 
occasionally, exchange blood transfusions (Ahmed, 2011).  Reagen et al. (2011) 
reported that ACS is responsible for up to 25% of sickle-related deaths. They 
also concluded that nearly half of the deaths due to ACS occur in children below 
the age of 20.  
Treatment 
Current treatments for SCD include the use of hydroxyurea, a cytotoxic 
and cytoreductive antimetabolite that inhibits ribonucleotide reductase and thus 
inhibits DNA synthesis (Aliyu et al., 2006). Treatment with hydroxyurea increases 
the production of fetal hemoglobin (HbF) while decreasing the production of HbS. 
Fetal hemoglobin is produced in the fetus during the last seven months of 
gestation and continues until approximately six months after birth, when the 
switch to HbA occurs. HbF has a stronger affinity for oxygen than HbS and HbA. 
Increasing the production of HbF in a patient with SCD can help increase 
oxygenation of peripheral tissues and lessen the adverse effects caused by HbS. 
Platt et al. (1994) concluded that the level of HbF shows a strong correlation with 
survival. They found that children with higher levels of HbF were more likely to 
survive into adulthood than those with lower levels of HbF. McGrann et al. (2011) 
found that hydroxyurea improves survival across SCD phenotypes; the survival 
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rate of patients with SCD taking hydroxyurea is compared to those who are not 
taking hydroxyurea and the results are illustrated in figure 1.  
 
Figure 1: Increased survival attributed to hydroxyurea. Patients with SCD taking hydroxyurea 
had a 10 year overall survival rate of 100% while those patients not taking hydroxyurea had 10% 
chance at 10 year survival (p<0.01). Figure taken from McGann, 2011. 
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In addition to increasing the production of fetal hemoglobin, hydroxyurea 
also reduces the production of neutrophils and reticulocytes by bone marrow. A 
high white blood cell count has been shown to increase morbidity and mortality in 
the SCD patient population; therefore it is beneficial to decrease the number of 
circulating white blood cells (Ware, 2010). The multiple positive effects of 
hydroxyurea can be seen in figure 2. Due to its effectiveness at increasing the 
production of fetal hemoglobin, hematologists prescribe hydroxyurea to many 
patients with SCD. The regimen for hydroxyurea often requires that patients take 
different doses throughout the week in order to be most beneficial. Compliance 
issues can result in an increased chance of a pain crisis and thus a 
hospitalization. 
Because the use of hydroxyurea can cause oral ulcers, hair loss, 
abdominal pain and melanonychia, patients are monitored for side effects during 
outpatient clinic visits. While some patients take hydroxyurea, others manage 
pain without it and rely on the use of pain medications such as morphine and 
oxycodone.  
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Figure 2: Positive effects of hydroxyurea on patients with SCD. (1) Stimulation of fetal 
hemoglobin production. (2) Decreased number of neutrophils and reticulocytes due to marrow 
cytotoxicity and ribonucleotide reductase. (3) Diminished adhesion of circulating neutrophils and 
reticulocytes. (4) Decreased hemolysis (5) Release of nitric oxide, which can lead to vasodilation 
and better vascular response. Figure taken from Ware, 2010.   
  
Because many patients with SCD are forced to live without a spleen, risk 
of infection is markedly increased in this population. Today, there are three 
measures that are used in order to diminish the risk of serious infection: penicillin 
prophylaxis, immunization against pneumococcal infection as well as the 
administration of folate, in the form of folic acid (Aliyu et al., 2006). Neonates are 
screened in the United States for SCD; if a baby tests positive, the standard of 
care is to treat with penicillin prophylaxis.  
Blood transfusions are also a common method for management of SCD. 
Replacing sickled RBCs with healthy ones can increase the carrying capacity for 
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oxygen and lead to improvement of conditions associated with anemia. Acute 
simple transfusions are most appropriate for patients experiencing symptomatic 
anemia, aplastic crisis, splenic or hepatic sequestration, ACS, or acute failure of 
multiple organs with severe anemia, as well as preparation of people with SCD 
for surgery (Aliyu et al., 2006). Some of the risks associated with transfusions 
include: contracting a transfusion-transmitted infection, development of 
unexpected RBC alloantibodies and autoimmune anemia after RBC 
alloimmunization (Danielson, 2002). For patients with SCD, the benefits outweigh 
the risks and many patients with SCD receive regularly scheduled transfusions in 
an outpatient setting.  
The only known cure for SCD is allogeneic hematopoietic stem cell 
transplant (HSCT), yet as Roth et al. (2012) explain, it is not used in many 
patients due to the significant risks associated with the procedure. Risks include: 
graft rejection, infection during transplantation, immunosuppression, graft versus 
host disease and death. For this reason, HSCT is only considered for those 
patients with the most severe cases of SCD, those that are not responding to 
other forms of treatment.  
Because a VOC can begin suddenly and progress rapidly, identifying the 
symptoms early can help a patient to seek the necessary help sooner. At Boston 
Children’s Hospital, patients and families are educated in the Hematology Clinic 
on self-care including how to identify and treat vaso-occlusive crises at home to 
prevent admissions when possible. Plans are individualized according to past 
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experiences with crises, allergies, and response to analgesics. Most patients 
take acetaminophen, non- steroidal anti-inflammatory drugs and an opioid. If the 
child does not respond well to the analgesics, then the child is brought to an 
emergency room (ER) for intravenous (IV) opioids. If an admission is required, at 
this pediatric tertiary medical center, patients are usually admitted to the general 
pediatrics floor from the ER and IV opioids by patient-controlled analgesia (PCA) 
in bolus and continuous forms are initiated. Once pain is managed, the patient is 
discharged with oral pain medications. During admissions, nurses reinforce this 
education.  
Quality of Life 
 Chronic and intermittent pain impacts the quality of life for a child. Health-
related quality of life (HRQL) is a tool that is used to assess a patient’s beliefs 
about how his health or medical treatments are affecting his ability to function 
and his overall well being (Panepinto, 2012). Figure 3 shows the HRQL of 
children with sickle cell disease on a spectrum that includes healthy children and 
those with other chronic diseases (Panepinto, 2012).  
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Figure 3: Health related quality of life in children with SCD compared to healthy children 
and those with chronic diseases. On a scale from 0 to 100 where 100 is the best physical 
functioning score, children with SCD rank 65.9. Figure taken from Panepinto, 2012. 
 
Progress in school can serve as an indication of how SCD is affecting a 
child. Information about school progress is collected during hospital admissions 
or during regularly scheduled outpatient hematology visits. SCD can cause 
significant problems in school because children are often forced to miss school 
days due to pain or subsequent hospitalizations. An IEP is an individualized 
educational plan, which intends to specialize an education program for those 
children with special needs or disabilities. A 504 plan stems from section 504 of 
the Rehabilitation Act and much like an IEP, its purpose is to make a specialized 
plan for disabled children to perform to their highest ability in school. 
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Current Research 
Ballas and Lusardi (2005) studied the patterns of hospital admissions and 
reasons for readmission in adult patients with SCD. They found that 
approximately 95% of the 1540 admissions of 136 patients were due to acute 
painful crises. Additionally, the intensity of pain scores decreased appreciably 
within the first 4 days after admission from an average of 8.7 ± 1.17 to 7.5 ± 1.00 
(P < 0.001) as measured on a pain assessment tool from 0-10. However, pain 
scores remained at a mean score of 7.4/10 until discharge (Ballas et al 2005).  
Zempsky et al (2008) performed a retrospective chart review of the 
outpatient clinic, emergency department and inpatient records for patients with 
SCD that were admitted for a VOC within a 2-year period.  They compared 
patients with an extended stay (≥ 5 days) to those with a shorter stay (< 5 days) 
with respect to a variety of factors including pain scores and opioid use 
(measured in morphine equivalents). Pain scores persisted in the moderate to 
severe range (≥ 5) in many patients despite administration of opioids that fell 
within the guidelines outlined by the American Pain Society (0.1-0.15mg/kg every 
2-4hrs). One suggestion for the results was central sensitization due to chronic, 
severe pain, which may alter a child’s perception of pain.  
Solodiuk et al (2013) performed a retrospective analysis of all pain 
intensity scores collected from 33,000 inpatient admissions at Boston Children’s 
Hospital over a two-year period. From nearly one million pain scores, the mean 
(1.4 in 2010 and 1.34 in 2011) and median (0 in 2010 and 2011) pain intensity 
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scores were low overall. There were four identifiable groups that had persistently 
high pain scores (mean ≥ 7). Patients with sickle cell vaso-occlusive episodes 
were one of the four categories with high pain scores (Solodiuk et al, 2013).  
Due to the widespread nature of SCD, health care costs associated with 
inpatient admissions remain high. Ashley-Koch et al (2000) reported that 
between 1989 and 1993, there were an average of 75,000 hospitalizations per 
year in the United States among individuals with sickle cell disease and as of 
1996, the cost of the hospitalizations had reached $475 million annually (Ashley-
Koch et al., 2000). It is our hope that these comparisons of sickle cell patients 
with high pain scores with those that have consistently lower pain scores will give 
insight into how to better manage pain in children with SCD. 
SPECIFIC AIMS 
Even though patients with SCD are given opioids in addition to non-
steroidal anti-inflammatory drugs, patients admitted for vaso-occlusive crises with 
SCD continue to exhibit high pain intensity scores. The purpose of this study is to 
better understand the differences between patients with high pain intensity 
scores as compared to those with low-moderate pain intensity scores within the 
sickle cell population.  
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The specific aims of the current study are:  
1. To compare similarities and differences in patients with persistently high 
pain intensity scores (mean ≥7) with patients with persistently low to 
moderate pain scores within the sickle cell patient population at Boston 
Children’s Hospital. 
2. To measure the relationships between persistently high pain scores and 
additional factors such as age, ethnicity, co-morbidities, location of pain, 
body mass index (BMI), hydroxyurea compliance, long-term drugs, clinical 
course and procedures, length of stay, and number of admissions per 
year. We also plan to look at the following social factors: insurance status, 
progress in school and family structure as well as compliance with clinic 
visits.  
Study Design 
A recent study administered by Solodiuk et al (2012) compiled pain 
intensity scores from all inpatients in 2010-2011 admitted at Boston Children’s 
Hospital. Results showed that patients with SCD were within a subgroup of one 
percent of the population that had persistently high pain scores (mean ≥7). These 
findings served as the basis for this study. Charts of patients with SCD admitted 
to Boston Children’s Hospital during 2010-2011 for a vaso-occlusive crisis, with 
documented demographic data and pain intensity scores were reviewed. The 
study protocol was determined to be exempt from review by the Boston 
Children’s Hospital Institutional Review Board because it was considered new 
 17 
research activity limited to review of health information on patients. The goal of 
this study was to expand our knowledge of the characteristics of patients with 
high pain intensity scores as well as those with low to moderate pain scores in 
order to focus efforts towards improving the care of patients with SCD. 
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METHODS 
  This study is a retrospective chart review comparing patient demographics 
and comorbidities in addition to clinical course. Patients were divided into two 
groups: a high pain group and a low to moderate pain group based on mean pain 
intensity scores as documented by the staff nurses caring for the patients during 
the time of the patient stay. Patient demographics (age, sex, ethnicity and race, 
admitting diagnosis, height and weight, admission date) were retrieved from the 
electronic medical records. Nurses used a variety of pain scales to document 
pain, including FLACC, NRS and Wong-Baker FACES pain scale. FLACC (Face, 
Legs, Activity, Cry and Consolability) pain assessment tool is validated for 
assessment of acute postoperative pain in newborns and children up to seven 
years old. This tool consists of 5 categories, each scored from 0-2, that when 
totaled results in a final score between 0 and 10 (Malviya et al., 2005). Self-
reported numerical rating scale (NRS) consists of numbers along the continuum.  
Children ages eight and older who are able to count and have an understanding 
of the progression of numbers can objectively relate to a concrete number 
corresponding to the intensity of the pain. The Wong Baker Faces scale is self-
report pain intensity scale with six cartoon faces depicting with progressive 
distress for children ages five and up (Hockenberry, 2009) (Solodiuk et al, 2013).   
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Data Collection  
 Data was extracted retrospectively from the electronic medical record for 
all patients admitted. Patients with SCD and persistently high pain scores as well 
as those with consistently lower pain scores were identified from this data and 
their charts were reviewed for patient characteristics and co-morbidities that may 
have contributed to their pain scores. Pain intensity scores were measured by 
computing the mean score during each admission while characteristics and co- 
morbidities of each patient were recorded qualitatively. We used notes recorded 
in the hospital record by the hematology department to assess whether each 
patient taking hydroxyurea had compliance issues. The results were analyzed 
using Student’s t-test in order to assess whether or not the two groups of patients 
have different mean values on given measures. P values are two-tailed and 
confidence intervals were calculated at the 95th percent level. 
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RESULTS 
 
We collected information on 71 admissions for vaso-occlusive crises from 
47 unique patients diagnosed with SCD within a two-year period (2010 and 
2011). One patient who had 17 admissions in the two-year period was excluded 
from the analysis in order to avoid skewing the results. Excluding this patient, the 
number of admissions per patient within the two-year period ranged from one to 
four with a mean of 1.5. Of the 71 admissions, 27 were categorized as 
persistently high pain, meaning the mean value of all the pain scores 
documented by bedside nurses was ≥ 7. The other 44 admissions had a mean 
pain score that was less than seven and were categorized as persistently low-
moderate pain. The 27 high pain admissions came from 16 patients. Thirty-four 
patients accounted for the 44 low-moderate pain admissions. Number of 
admissions per patient ranged from one to three in the low-moderate pain group. 
Three patients fell into both the high pain and low-moderate pain categories 
during different admissions.  
 
 
 
 
 
 
Figure 4: High pain and low-moderate pain unique patients. Three patients fell into both 
categories.  
34 16 3 
Low-Moderate Pain 
Patients  
High Pain Patients  
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Patients of the high pain group and low-moderate pain group were 
matched for age, gender and race. Of the 47 unique patients, 21 were female 
(45%) and 26 were male (55%). The mean age for patients upon admission was 
14 years. Race and ethnicity were self-reported by patients and or parents upon 
admission. Eighty-five percent of patients included in the study were black or 
African American-non-Hispanic, 11% were Hispanic and 4% identified as other. 
The mean BMI at admission was 20.38. The overall average length of stay for 
each admission was six days and the mean total length of stay within a two-year 
period was approximately eight days. The majority of patients admitted had 
HbSS, but many had HbSC and others had HbSbeta-thalassemia. The 
breakdown of unique patients by type of SCD can be seen in table 1.  
Table 1: Type of sickle cell disease in each patient group. Breakdown of patients by type of 
SCD.  
Type of SCD 
High Pain 
Patients 
Low-Moderate 
Pain Patients 
Patients with 
High and 
Low-Moderate 
Pain 
Admission Total 
HbSS 8 17 1 26 
HbSC 2 10 2 14 
HBS/beta-thal 3 4 0 7 
 
The most common location for pain in all patients was in the legs, followed 
by equal accounts of pain in the arms, chest and back. Other locations of pain 
included the shoulders, elbows, thighs, calves, knees, hips, sacrum, buttocks, 
abdomen, ribs, and head. Some patients were admitted for fever, headache, 
coughing, wheezing or general respiratory distress in addition to a vaso-occlusive 
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crisis. The majority of patient admissions reported pain in one location, but the 
number of locations of pain ranged from zero to six and this is illustrated in table 
2. Bilateral arm or leg pain was categorized as pain in two sites. There were four 
types of health insurance within the patient population: Medicare, in-state 
Medicaid, commercial insurance from a health maintenance organization (HMO), 
and commercial insurance from another source. Health insurance breakdown 
can be seen in table 3.  
Table 2: Number of sites of pain by admission. Admissions broken down by number of sites of 
pain. 
Number of sites of pain Number of Admissions 
0 7 
1 20 
2 17 
3 13 
4 6 
5 5 
6 3 
 
Table 3: Insurance types for unique patients.  Patients broken down by insurance status. 
Type of Health 
Insurance 
 
Number 
of 
Total 
Patients 
High 
Pain 
Patien
ts 
Low-
Moderate 
Pain 
Patients 
Both High and Low-
Moderate 
Pain Patients 
Medicare 1 1 0 0 
In-state Medicaid 18 6 12 0 
Commercial 
HMO 11 4 5 2 
Commercial 
other 17 4 14 1 
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The majority of admissions (35%) occurred in the fall (n=25). Equal 
amounts occurred in the summer and winter (24%; n=17). The fewest admissions 
(17%) occurred during the spring (n=12). Operational definitions for each season 
are reported in appendix A.  
Co-morbidities  
Although the majority of admissions showed no co-morbidities, (n=44), 14 
admissions had one co-morbidity, eight admissions had two, three admissions 
had three co-morbidities and two admissions had four co-morbidities. Some of 
the conditions listed were moyamoya, diabetes, autism, pelvic inflammatory 
disease, and asthma.  
Clinical Course  
Upon chart review, we found the majority of patients in both the high pain 
(82%) and low-moderate pain (82%) groups followed the usual clinical course. 
Reasons for an abnormal clinical course included transfer to the intensive care 
unit, admission from other hospitals, and transfusion reactions or high fevers, 
which lengthened the hospital stay.  
Length of Stay  
Length of stay, shown in figure 4, varied significantly between the groups, 
with a median length of stay per admission of seven days for high pain patients 
and four days for low-moderate pain patients (p=0.048). Hemoglobin levels upon 
admission did not vary significantly between groups, with a median value of 9.2 
for high pain and 9.7 for low-moderate pain (p=0.424). These results are 
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illustrated in figure 5. Normal hemoglobin values for healthy children can be 
found in appendix B.  
BMI 
There was no significant difference in the mean BMIs at admission of 
patients in the high pain group (median =19.85) versus the low-moderate pain 
group (median =19.35) (p=0.163). The comparison in BMI’s can be seen in figure 
6.  
 
Figure 5: Length of Stay per Admission. Comparison of high pain and low-moderate pain 
patients, with respect to length of stay per admission for admissions within the two-year period.  
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Figure 6: Hemoglobin Level. Comparison of high pain and low-moderate pain patients, with 
respect to hemoglobin levels upon admission.  
 
 
 
Figure 7: Body Mass Index. Comparison of high pain and low-moderate pain patients, with 
respect to body mass index at time of admission.  
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scores (p=0.002). The median total length of stay for high pain patients was 11 
days and for low-moderate pain patients it was six days. These results can be 
seen in figure 7.  
 
Figure 8: Total Length of Stay in Two-year Period by Patient. Comparison of total length of 
stays for two-year period between patients with high pain and low-moderate pain. 
 
Long-Term Medications  
Any long-term home medications that patients were taking upon 
admission to the hospital were recorded. Medications to alleviate pain were the 
most common drugs in both the high pain and low-moderate pain groups.  Stool 
softeners and laxatives were the second most prevalent drug. Folic acid was 
recorded for eight high pain admissions and 24 low-moderate pain admissions. 
Other prevalent long-term drugs included bronchodilators, antibiotics, 
antihistamines, iron chelators, antacids, anti-hypertensive drugs and leukotriene 
receptor antagonists. Table 4 shows the distribution of long term home 
medications being taken during high pain admissions, low-moderate pain 
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admissions, and total admissions overall. A list of medications that fell into each 
category can be found in Appendix C. 
Table 4: Long-Term Home Medications. Long-term drugs being taken by patients during high 
pain admissions, low-moderate pain admissions and total admissions overall, broken down into 
drug type. 
Type of Medication 
High Pain 
Admissions 
Low-
Moderate 
Pain 
Admissions 
Total 
Admissions 
Pain Medication 41 91 132 
Stool Softener/Laxative 21 39 60 
Folic Acid 8 24 32 
Bronchodilator 4 20 24 
Antibiotics 3 19 22 
Antihistamines 1 14 15 
Corticosteroid 5 8 13 
Iron Chelators 1 7 8 
Antacids 4 3 7 
Antihypertensive 3 3 6 
Lukotriene Receptor 
Antagonists 0 3 3 
Antiemetic 0 1 1 
Diuretic 0 1 1 
Anti-depressant 0 1 1 
Anti-psychotic 0 1 1 
 
Medical Consultations 
 
When pediatric patients with SCD are admitted to Boston Children’s 
Hospital, usually from the ER, they are admitted to the general pediatrics floor. 
While in the ER, consults with hematology are requested. A consult with the pain 
team is scheduled for any SCD patient experiencing pain due to a vaso-occlusive 
crisis. The difference in mean number of medical consultations during 
admissions for high pain admissions versus admissions for low-moderate pain 
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was shown to be non- significant (p=0.158). The breakdown for medical 
consultations in both groups of patients can be seen in table 5. 
Table 5: Consultations. Type and number of scheduled consultations made for high pain 
admissions and low-moderate pain admissions.  
Consultation 
High Pain 
Admissions 
Low-
Moderate 
Pain 
Admissions 
Pain Team  24 32 
Neurology  7 1 
IV Team  11 16 
Integrative Therapy  3 0 
General Surgery  1 0 
Psychiatry  7 0 
Rheumatology  1 0 
Neurosurgery 1 1 
Nephrology  1 2 
Blood Bank  0 3 
Plastic Surgery  0 1 
Nutrition  0 1 
Therapeutic 
Apheresis  0 3 
Interventional 
Radiology 0 1 
Cardiology  0 2 
Pulmonology 0 1 
Allergy/Immunology 0 1 
Infectious Disease  0 2 
Endocrinology 0 1 
Orthopedics 0 1 
Otolaryngology 0 1 
Total Medical 
Consults  56 70 
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Hydroxyurea Compliance 
Hematology notes were written as documentation by exception. Of the 27 
high pain admissions, 9 patients were not taking hydroxyurea at the time of 
admit. 18 patients were taking hydroxyurea at the time of admit and of those 18, 
14 were compliant and 4 were noted to have problems with compliance. Of the 
44 low-moderate pain admissions, 22 were not taking hydroxyurea at time of 
admit, while 22 were taking hydroxyurea. Of those on hydroxyurea, 14 were 
noted as compliant and 8 were noted to have poor compliance with the 
medication regimen. These results can be seen in figure 8.
 
Figure 9: Hydroxyurea Compliance. Comparison of hydroxyurea compliance in high pain 
admissions to low-moderate pain admissions. 
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patient in the low-moderate pain group was currently on a 504 plan at school. We 
also noted concerns about school absences were expressed frequently by the 
patient or the patient’s family to the hematology team. Many patients were falling 
behind in school due to frequently missed days of school. Some received tutoring 
through school, some received inpatient tutoring during hospitalizations and 
others received no tutoring at all. 
Family Structure 
 In addition to information on schooling, we also gathered data on the 
family structure and living situation of each patient. We found that the majority of 
patients were living in single parent homes. Table 6 shows the breakdown of 
family living situations by patient group. One patient from the high pain group is 
unaccounted for because no information on family structure was recorded.  
Table 6: Living Situation for Patients. Parent or family member living with each patient.  
Living Situation 
High 
Pain 
Patients  
Low-
moderate 
Pain 
Patients  
High and Low 
Pain Patients  
Only mother  7 18 3 
Only father 0 1 0 
Both parents  1 8 0 
One parent and one step-
parent  2 2 0 
Independently Living  1 2 0 
Living with relatives  1 0 0 
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DISCUSSION 
 
 Comparison between these two groups of patients with SCD, experiencing 
a VOC, indicates that although differences between the groups exist, they are 
similar with respect to most of the factors we investigated. Our results show that 
sickle cell patients with high pain scores do not differ greatly from those with low-
moderate pain scores with respect to hemoglobin levels or BMI at the time of 
admission. The median hemoglobin value was 9.2 for high pain patients and 9.7 
for low-moderate pain patients. Median BMI values were 19.85 for high pain 
admissions and 19.35 for low-moderate pain admissions.  
We gathered information on all patients with SCD admitted for a VOC 
between 2010 and 2011. The majority of admissions occurred in the fall. This 
was surprising since extremes in temperature are associated with an increased 
risk for vaso-occlusive crises and temperatures within this range are most often 
seen during the summer and winter (Bender et al., 2003). Brandow et al. (2013) 
conducted a study to determine whether patients with SCD had increased 
sensitivity to cold and heat. The compared patients with SCD to healthy matched 
controls and found that SCD patients felt cold and heat pain at a temperature 
closer to 32°C than healthy controls. They recommend additional research into 
the mechanism underlying this sensitivity but suggested that it may be attributed 
to sensitization of either central or peripheral neurons, which in turn, contributes 
to the development of pain. Continued patient education about the importance of 
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avoiding any circumstances involving extreme temperatures may be useful in 
reducing the number of admissions throughout the year.  
A notable difference between high pain and low to moderate pain patients 
was length of stay of each individual admission, which was significantly higher in 
patients with high pain (seven days) versus low-moderate pain (four days). The 
total length of stay for patients with high pain (11 days) was significantly greater 
than patients with low-moderate pain (six days). Health care providers strive to 
alleviate pain in patients, and that process can require additional doses of pain 
medication and more time in the hospital for patients with persistently high pain 
scores. Further research is needed to understand the relationship between 
length of stay and high pain scores. Location of pain was most common in the 
extremities, chest and back, which have been shown to be common sources of 
pain in previous studies. These results are consistent with other reports in the 
literature that have described the pain crisis as a sudden onset of pain in the 
lower back or one or more joints of the extremities (Ballas et al., 2012).  
One reason for extended stays of patients with high pain scores could be 
due to the need for medical consultations. The total number of medical 
consultations scheduled from the 27 high pain admissions was 56. For the 44 
low-moderate pain admissions, the number of consults was 70. Overall, there 
were a greater average number of medical consultations made for patients with 
high pain than patients with low-moderate pain.  
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The low-moderate pain group had no consultations for psychiatry, while 
the high pain group had seven consultations made. Of these seven psychiatric 
consultations, six had no diagnosis and one had a diagnosis of generalized 
anxiety disorder. Carroll et al (2012) compared two groups of patients with SCD, 
those considered high utilizing patients, who had over four emergent care visits 
within 12 months to low utilizing patients. They found that with respect to low 
utilizers, the prevalence of psychiatric illness in family members of high utilizers 
was three times greater. Further research into the correlation between psychiatric 
health and pain in patients with SCD would serve as a valuable resource.  
The presence of co-morbidities may be one cause for medical 
consultations. Although the majority of admissions had no co-morbidities 
recorded (n=44), of those patients that did have recorded co-morbidities, we 
found a wide variety of conditions. There were two cases of moyamoya disease 
in the high pain admissions and one case in the low-moderate pain admissions. 
One case of hemosiderosis was recorded in each group. Hemosiderosis may be 
a result of excess iron in the blood due to RBC hemolysis and the release of 
hemoglobin into the bloodstream. Two cases of asthma were found in the low 
pain group and history of stroke was noted in one admission from each group. 
Additional co-morbidities were found in isolated cases including diabetes, pelvic 
inflammatory disease, lupus, seizure disorder, and pancreatitis. 
 In both the high and low-moderate pain groups, HbSS was the most 
frequently found type of SCD. HbSS is also the most common form of SCD found 
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in the population. Sixty-two percent (n=8) of the high pain patients and 55% 
(n=17) of the low-moderate pain group had HbSS. In the high pain group, the 
second most common type of sickle cell was HbS/beta thalassemia and the least 
common was HbSC. For the low-moderate pain group, HbSC was more common 
that HBS/beta thalassemia. In those three patients that fell into both categories, 
there was one case of HbSS and two cases of HbSC. Although HbSS was the 
most common type of SCD in our patient population, it is not clear that HbSS 
causes more pain than either of the other two types of SCD found in this 
population.   
 Analysis of type of health insurance by admission found that the most 
common types of insurance within the total sample were: in-state Medicaid (38%) 
(n=18) and commercial insurance not provided by an HMO (36%). A recent 
retrospective study examined self-reported pain scores in an emergency 
department in order to determine which factors are associated with higher pain 
scores. They found a positive correlation between higher-self reported pain 
scores and Medicaid insurance status compared to private insurance, self-pay, 
other forms of insurance (Marco et al., 2013). This was not the case in our study 
population. Within the high pain group, 40% of patients had in-state Medicaid 
while 53% had commercial insurance, either from an HMO or from another 
source. In the low-moderate group, 39% had in-state Medicaid and 61% had 
some form of commercial insurance. For the three patients that fell into both 
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categories, two received commercial insurance from an HMO and one had 
commercial insurance from another source.  
A previous study found that of patients admitted to the ER, those 
experiencing a sickle cell crisis reported the highest pain scores (Marco et al., 
2013). The majority of patients in both the high and low-moderate pain groups 
followed the usual clinical course that begins in the ER. Staff is encouraged to 
insert an IV in SCD patients experiencing a VOC within 30 minutes of arrival. The 
patient then receives two to three doses of IV opioids and IV ketorolac. If pain is 
still not well controlled, the patient will receive PCA and a continuous infusion of 
opioids.  
Marco et al. (2006) investigated the use of educational materials in the 
form of a brochure and a video to teach patients in the ER about the self-reported 
pain scales. They looked at two groups of patients, participants who used the 
educational material and a control group. They found that of those patients who 
read the brochure and watched the video, 26% of them reported a statistically 
significant decrease in self-reported pain scores by two or more points. Nurses at 
Boston Children’s Hospital use a flip chart to educate parents about pain in this 
population. Research into the amount of available education and the techniques 
of explaining the current pain tools used by the ER and the hematology clinic to 
assess pain in patients with SCD is warranted.   
 Collecting information on the use of long-term medications allowed insight 
into the medication routine followed by patients outside of the hospital setting. 
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Pain medication was the most common medicine taken at home. Medication to 
relieve pain is often prescribed to a patient to take while experiencing a VOC. 
Opioids act on the enteric nervous system and bind to the myenteric and 
submucosal plexuses. This causes decreased fluid secretion and sphincter 
dysfunction (Brock, et al., 2012). The high number of stool softeners seen in our 
patient population is likely due to an attempt to rectify the constipation and 
general gastrointestinal discomfort caused by the pain medications. Another 
common medication found in both groups of patients was folic acid, the synthetic 
form of folate, a water-soluble B vitamin found in many different foods including 
leafy green vegetables and citrus fruits. Folic acid helps to produce and maintain 
new cells, thus an adequate amount is desirable in patients with SCD. 
 About two thirds of the high pain admissions took hydroxyurea at home. 
The majority of patients on hydroxyurea were compliant (78%) (n=14). Half of the 
low-moderate pain admissions came from patients who were on a hydroxyurea 
regimen and of those, 64% were noted to be compliant (n=22). Because of the 
effectiveness of hydroxyurea at increasing fetal hemoglobin production, we 
expected that a higher percentage of patients in the high pain group would be on 
a hydroxyurea regimen.  
The number of patients living in homes with single mothers was very high 
within this patient population. In both the high pain and low-moderate pain group, 
this was the case for 58% (n=7 for high pain and n=18 for low-moderate pain) of 
patients. Of the three patients who fell into both categories, the figure was 100%. 
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A hospitalization for a pain crisis is challenging for any family, but for those single 
parent families, it can be even more difficult since the parent has to split time 
between the child in the hospital, siblings who are living at home, work and other 
obligations. Continued visits from social work in the inpatient as well as the 
outpatient setting can provide additional support for those families with single 
parents. Research into the stressors of families with SCD is needed in order to 
guide best practice in supporting these families.   
 The results of our analysis showed that six patients overall of the 47 
unique patients were either on an IEP or a 504 in school. Because of the small 
sample size, we did not expect this number to be as high as it is. Further 
research, into the effects of sickle cell disease on school performance are 
warranted.   
 The strength of this study is the ability to compare two groups of patients, 
with similar demographics, both quantitatively as well as qualitatively. In addition 
to assessing the length of stay and the values of hemoglobin, we were also able 
to use a combination of notes from the hematology team as well as the social 
work team to assess school progress and family structure.  
One limitation of this is that it was performed at one location in the city of 
Boston and thus results may not be applicable to other locations. In addition, 
because it was a retrospective study, results rely on the accuracy of information 
entered into the electronic medical record. Another limitation of this study was the 
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small sample size. The number of admissions due to VOC varies year to year so 
inclusion of data from a period of time greater than two years would be beneficial.  
Our results support the adoption of a validated pain assessment tool to be 
used specifically for patients with sickle cell disease. A pain scale that accounts 
for a certain amount of baseline pain, frequently seen in sickle cell patients, 
would prove to be helpful in better assessing the unique pain caused by a vaso-
occlusive crisis. Perhaps using a tool such as this could help to better distinguish 
chronic pain from pain resultant from a VOC.  
Jacob et al. (2012) found that the use of smartphones by patients with 
sickle cell disease in order to access a web-based e-diary increased 
communication between patients and health care providers. Making the health 
care provider aware of the occurrence of pain and symptoms resulted in a more 
timely response. Supplying each patient with a smartphone as well as employing 
a health care provider dedicated to responding to patients may be too costly of a 
solution for most, but the idea of real time communication is a promising one.  
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Conclusion 
 
The results of this study show that pain continues to persist in patients 
with SCD, despite the administration of IV analgesics during admissions, home 
analgesics and the use of hydroxyurea therapy. Although there are differences 
noted between high pain and low to moderate pain patients, these differences 
are not so significant that either group should be treated differently. The 
development and implementation of a method of intervention that could decrease 
the number of pain crises for both groups of patients would serve as a beneficial 
use of resources.  
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Appendix A: Operational Definitions of Each Season.  
Winter  December 21- March 20 
Spring  March 21- June 21 
Summer June 22- September 22 
Fall  September 23- December 20 
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Appendix B: Normal Hemoglobin Levels for Children. Table adapted from 
Irwin, 2001.  
 
Age  Hemoglobin Level (g/dL)  
Birth- 6 months 18.5- 12.6 
6 months- 2 years  12.0 
2 years – 6 years  12.5 
6 years to 12 years 13.5 
12 years to 18 years: MALES 14.5 
12 years to 18 years: FEMALES 14.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 42 
Appendix C: Types of Medication in Each Category.  
Pain Medications: 
-Acetaminophen  
-Ibuprofen 
-Oxycodone 
-Morphine 
-Hydromorphone 
-Methadone  
- Aspirin  
-Naproxen 
-Gabapentin  
 
Stool Softener and Laxatives:  
Docusate-Senna  
Docusate  
Senna  
Polyethylene Glycol  
 
Bronchodilators:  
Fluticasone-Salmeterol 
Albuterol  
Aerochamber 
 
Antibiotics:  
Amoxicillin  
Amoxicillin-Penicillin 
Penicillin  
Penicillin V Potassium  
ZZZPenicillin 
Erythromycin 
Levofloxacin  
 
Antihistamine: 
Loratidine  
Diphenhydramine  
Cetirizine  
 
Corticosteroids:  
Fluticasone  
 
Iron Chelators:  
Deferoxamine  
Deferasirox 
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Antacid:  
Omeprazole  
Raniditine 
Bismuth  
 
Antihypertensive Drugs:  
Losartan  
Atenolol  
Betaxolol  
Verapamil  
Amlodipine 
 
Lukeotriene Receptor Antagonist:  
Montelukast  
Zafirlukast (Accolate)  
 
Antiemetic: 
Ondansetron 
 
Diuretic:  
Amiloride  
 
Anti-Depressants: 
Amitriptyline 
 
Anti-Psychotic:  
Risperidone  
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